Mitch A. Phelps, PhD

Director of the Pharmacoanalytical Shared Resource, OSU Comprehensive Cancer Center
B.A. in Physics, Ohio Wesleyan University
M.A. in Business Management, Labor and Human Resources, The Ohio State University
Ph.D in Biophysics, The Ohio State University

Mitch A. Phelps, PhD is Director of the OSU Comprehensive Cancer Center Pharmacoanalytical Shared Resource, which supports pharmacokinetic (PK)/pharmacodynamic (PD) study design and conduct for pre-clinical and clinical drug development. Dr. Phelps has directed PK/PD studies in preclinical disease models and in early phase clinical trials for nearly ten years.  His research group focuses on development of small molecule and oligonucleotide anticancer and immune-modulatory agents here at OSU, using statistical modeling and simulation of PK/PD data to understand how genetic and other factors contribute to differences in therapy outcomes among individuals.  Dr. Phelps is an associate professor in the College of Pharmacy Division of Pharmaceutics and Pharmaceutical Chemistry and in the College of Medicine Department of Pharmacology.

Research Interests

Preclinical Disease

Early Phase Clinical Trials

Development of Small Molecule and Oligonucleotide Anticancer and Immune Agents

Honors

  • 2005 Outstanding Graduate Student Award. .
  • 2003-2004 Predoctoral Fellowship. .
  • 2004 Predoctoral Fellowship. .
  • 2003 Ray Travel Award. .
  • 2001 Hazel Brown Teaching Award. .

Journal Articles

2016

  • 2016, "Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents." AAPS JOURNAL 18, no. 3,

2014

  • 2014, "A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery." NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 10, no. 2,

2013

  • 2013, "Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes." NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 9, no. 4,
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM, 2013, "Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia." Leukemia Research E-pub pii: S0145-2126(13)00192-6, 192-6 - 192-6.
  • Mortazavi,Amir; Ling,Yonghua; Martin,Ludmila,Katherine; Wei,Lai; Phelps,Mitch,A; Liu,Zhongfa; Harper,Erica,J; Ivy,S,Percy; Wu,Xin; Zhou,Bing-Sen; Liu,Xiyong; Deam,Deidre; Monk,J,Paul; Hicks,William,J; Yen,Yun; Otterson,Gregory,A; Grever,Michael,R; Bekaii-Saab,Tanios, 2013, "A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors." Investigational New Drugs 31, no. 3, 685-695 - 685-695.
  • Ji,Jia; Mould,Diane,R; Blum,Kristie,A; Ruppert,Amy,S; Poi,Ming; Zhao,Yuan; Johnson,Amy,J; Byrd,John,C; Grever,Michael,R; Phelps,Mitch,A, 2013, "A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol." CLINICAL CANCER RESEARCH 19, no. 5, 1269-1280 - 1269-1280.
  • Mao,Yicheng; Triantafillou,Georgia; Hertlein,Erin; Towns,William; Stefanovski,Matthew; Mo,Xiaokui; Jarjoura,David; Phelps,Mitch; Marcucci,Guido; Lee,Ly,James; Goldenberg,David,M; Lee,Robert,J; Byrd,John,C; Muthusamy,Natarajan, 2013, "Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74(+) B-cell Malignancies." CLINICAL CANCER RESEARCH 19, no. 2, 347-356 - 347-356.
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W, 2013, "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." Leukemia and Lymphoma E-pub ahead of print, 01 - 01.
  • 2013, "CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.." Drug metabolism and drug interactions 28, no. 1,
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA, 2013, "Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.." Clinical Pharmacokinetics 52, no. 8, 705-12 - 705-12.
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC, 2013, "avopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma." Am J Hematol Epub, Epub - Epub.
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA, 2013, "Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.." J Pharm Biomed Anal 88, no. 25, 262-8 - 262-8.

2012

  • Kitzmiller,Joseph,P; Embi,Peter,J; Manickam,Kandamurugu; Sweet,Kevin,M; Phelps,Mitch,A; Jackson,Rebecca,D; Marsh,Clay,B; Sadee,Wolfgang, 2012, "Program in Pharmacogenomics at the Ohio State University Medical Center." PHARMACOGENOMICS 13, no. 7, 751-756 - 751-756.
  • Stephens,Deborah,M; Ruppert,Amy,S; Blum,Kristie; Jones,Jeffrey; Flynn,Joseph,M; Johnson,Amy,J; Ji,Jia; Phelps,Mitch,A; Grever,Michael,R; Byrd,John,C, 2012, "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 97, no. 3, 423-427 - 423-427.
  • 2012, "Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses." American Journal of Veterinary Research 73, no. 9,
  • Bill,Matthew,A; Nicholas,Courtney; Mace,Thomas,A; Etter,Jonathan,P; Li,Chenglong; Schwartz,Eric,B; Fuchs,James,R; Young,Gregory,S; Lin,Li; Lin,Jiayuh; He,Lei; Phelps,Mitch; Li,Pui-Kai; Lesinski,Gregory,B, 2012, "Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines." PLOS ONE 7, no. 8, e40724 - e40724.
  • Hofmeister,Craig,C; Yang,Xiaoxia; Phelps,Mitch,A, 2012, "Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply." JOURNAL OF CLINICAL ONCOLOGY 30, no. 3, 341-342 - 341-342.
  • 2012, "Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 25, no. 10,
  • 2012, "Acetaminophen pediatric dose selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children.." Clinical pediatrics 51, no. 11,
  • 2012, "Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses." American Journal of Veterinary Research 73, no. 3,
  • Spatola,Ronald,A; Thangavelu,Mirunalni; Upadhyayula,Vijayasaradhi; Lee,Seungsoo; Phelps,Mitch,A; Chandler,Heather,L, 2012, "Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells." AMERICAN JOURNAL OF VETERINARY RESEARCH 73, no. 12, 1987-1995 - 1987-1995.
  • He,Lei; Grecula,John,C; Ling,Yonghua; Enzerra,Michael,D; Ammirati,Mario; Kendra,Kari; Cavaliere,Robert; Mayr,Nina; McGregor,John; Olencki,Thomas; Mrozek,Ewa; Matharbootham,Mani; Oluigbo,Chima; Phelps,Mitch,A, 2012, "Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue." JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 905, 141-144 - 141-144.
  • Rozewski,Darlene,M; Herman,Sarah,EM; Towns,William,H; Mahoney,Emilia; Stefanovski,Matthew,R; Shin,Jungook,D; Yang,Xiaoxia; Gao,Yue; Li,Xiaobai; Jarjoura,David; Byrd,John,C; Johnson,Amy,J; Phelps,Mitch,A, 2012, "Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice." AAPS JOURNAL 14, no. 4, 872-882 - 872-882.

2011

  • Hofmeister CC*, Yang X*, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM, Kraut EH, Hicks WJ, Chan KK, Chen C, Farag SS, Grever MR, Byrd JC, Phelps MA, 2011, "Phase I Trial of Lenalidomide and CCI‐779 in Patients with Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein." Journal of Clinical Oncology 29, no. 25, 3427-3434 - 3427-3434.
  • Saradhi UV*, Gupta SV*, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA**, Chan KK**, 2011, "Characterization of silvestrol pharmacokinetics in mice using liquid chromatography–tandem mass spectrometry." AAPS Journal 13, no. 3, 347-356 - 347-356.
  • Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC, 2011, "Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." Leukemia 25, no. 9, 1444-1451 - 1444-1451.
  • Bekaii-Saab T*; Phelps MA*; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA, 2011, "Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 29, no. 17, 2357-2363 - 2357-2363.
  • Kitzmiller JP, Groen DK, Phelps MA, Sadee W, 2011, "Pharmacogenomic Testing: Relevance in Medical Practice." Cleveland Clinic Journal of Medicine 78, no. 4, 243-257 - 243-257.
  • 2011, "miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival." CANCER RESEARCH 71, no. 24,
  • Andritsos L, Jaglowski S, Stark A, Lin T, Jones J, Heerema N, Blum K, Flynn J, Moran M, Mitchell S, Lozanski G, Johnson A, Mahoney E, Phelps M, Byrd J, Grever M, 2011, "Low incidence of opportunistic infections with single agent flavopiridol for treatment of chronic lymphocytic leukemia." Blood
  • 2011, "6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.." Pain medicine (Malden, Mass.) 12, no. 12,
  • Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, Phelps MA, Grever MR, Lucas DM, 2011, "Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells." AAPS Journal 13, no. 3, 357-364 - 357-364.

2010

  • Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai J, Wolfson A, Lustberg M, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, and Shah MH, 2010, "A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors." Investigational New Drugs 30, no. 2, 629-638 - 629-638.
  • Blum W; Klisovic RB; Becker H; Yang X; Rozewski DM; Phelps MA; Garzon R; Walker A; Chandler JC; Whitman SP; Curfman J; Liu S; Schaaf L; Mickle J; Kefauver C; Devine SM; Grever MR; Marcucci G; Byrd JC, 2010, "Dose escalation of lenalidomide in relapsed or refractory acute leukemias.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 28, no. 33, 4919-4925 - 4919-4925.
  • 2010, "REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.." Clinical cancer research : an official journal of the American Association for Cancer Research 16, no. 22,
  • Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA, 2010, "Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.." Plos One 5, no. 11, e13792 - e13792.
  • Blum W*; Phelps MA*; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM; Johnson A; Schaaf LJ; Byrd JC; Marcucci G; Grever MR, 2010, "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica 95, no. 7, 1098-1105 - 1098-1105.
  • Riesen SC, Ni W, Carnes CA, Lindsey KJ, Phelps MA, Schober KE, 2010, "Pharmacokinetics of oral ivabradine in cats." Journal of Veterinary Pharmacology and Therapeutics 34, no. 5, 469-475 - 469-475.

2009

  • Yang X; Zhao X; Phelps MA; Piao L; Rozewski DM; Liu Q; Lee LJ; Marcucci G; Grever MR; Byrd JC; Dalton JT; Lee RJ, 2009, "A novel liposomal formulation of flavopiridol.." International Journal Of Pharmaceutics 365, no. 1-2, 170-174 - 170-174.
  • Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT, 2009, "Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.." Blood 113, no. 12, 2637-2645 - 2637-2645.
  • Lin TS; Stock W; Xu H; Phelps MA; Lucas MS; Guster SK; Briggs BR; Cheney C; Porcu P; Flinn IW; Grever MR; Dalton JT; Byrd JC, 2009, "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia.." Leukemia & Lymphoma 50, no. 12, 1958-1963 - 1958-1963.
  • Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC, 2009, "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology 27, no. 35, 6012-6018 - 6012-6018.

2008

  • 2008, "Intracellular processing of riboflavin in human breast cancer cells.." Mol Pharm 5, no. 5,
  • 2008, "Inhibitors of tubulin assembly identified through screening a compound library.." Chem Biol Drug Des 72, no. 6,
  • Liu Q; Farley KL; Johnson AJ; Muthusamy N; Hofmeister CC; Blum KA; Schaaf LJ; Grever MR; Byrd JC; Dalton JT; Phelps MA, 2008, "Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.." Therapeutic Drug Monitoring 30, no. 5, 620 - 620.
  • Phelps,Mitch,A; Rozewski,Darlene,M; Johnston,Jeffrey,S; Farley,Katherine,L; Albanese,Katie,A; Byrd,John,C; Lin,Thomas,S; Grever,Michael,R; Dalton,James,T, 2008, "Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule." JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 868, no. 1-2, 110-115 - 110-115.
  • Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT, 2008, "Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.." Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences 871, no. 1, 15-21 - 15-21.

2007

  • Christian BA, Fischer B, Blum KA, Brooker-McEldowney M, Moran ME, Andritsos LA, Phelps MA, Dalton JT, Colevas AD, Byrd JC, Grever MR, Lin TS, 2007, "Flavopiridol in Chronic Lymphocytic Leukemia." Clinical Leukemia 5, no. 1, 292-297 - 292-297.
  • Byrd,John,C; Lin,Thomas,S; Dalton,James,T; Wu,Di; Phelps,Mitch,A; Fischer,Beth; Moran,Mollie; Blum,Kristie,A; Rovin,Brad; Brooker-McEldowney,Michelle; Broering,Sarah; Schaaf,Larry,J; Johnson,Amy,J; Lucas,David,M; Heerema,Nyla,A; Lozanski,Gerard; Young,Donn,C; Suarez,Jose-Ramon; Colevas,A,Dimitrios; Grever,Michael,R, 2007, "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia." Blood 109, no. 2, 399-404 - 399-404.

2006

  • 2006, "Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides.." Bioorg Med Chem 14, no. 16,
  • 2006, "Recognition, co-internalization, and recycling of an avian riboflavin carrier protein in human placental trophoblasts.." The Journal of pharmacology and experimental therapeutics 317, no. 2,

2005

  • Gao,W,Q; Reiser,P,J; Coss,C,C; Phelps,M,A; Kearbey,J,D; Miller,D,D; Dalton,J,T, 2005, "Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats." Endocrinology 146, no. 11, 4887-4897 - 4887-4897.

2004

  • 2004, "Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry." ANALYTICAL CHEMISTRY 76, no. 3,
  • 2004, "A novel rhodamine-riboflavin conjugate probe exhibits distinct fluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies.." Mol Pharm 1, no. 4,
  • 2004, "Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2).." Biochemistry 43, no. 36,

2003

  • 2003, "Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin.." J Pharmacol Exp Ther 306, no. 2,
  • 2003, "Cytoskeletal motors and cargo in membrane trafficking: opportunities for high specificity in drug intervention.." Drug Discov Today 8, no. 11,

2002

  • 2002, "Modeling of active transport systems.." Adv Drug Deliv Rev 54, no. 3,